

## HK2 (Hexokinase II) Antibody (N-term)

Catalog\_no: AB2578

Reactivity:

Category: 抗原抗体

Size: 100µL/50µL

Immunogen: HUMAN:91-121

This HK2 (Hexokinase II) antibody is generated from rabbits immunized with a KLH Specificity:

conjugated synthetic peptide between 91-121 amino acids from the N-terminal region of

human HK2 (Hexokinase II).

Dilution: WB,1:1000;IHC-P,1:50~100;

Purification: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This

antibody is purified through a protein G column, eluted with high and low pH buffers

and neutralized immediately, followed by dialysis against PBS.

Hexokinase-2, Hexokinase type II, HK II, Muscle form hexokinase, HK2 Other\_name:

Isotype: Rabbit Ig

Background: In vertebrates there are four major glucose-phosphorylating isoenzymes, designated

> hexokinase I, II, III, and IV. Hexokinase is an allosteric enzyme inhibited by its product GLC-6-P. Hexokinase activity is involved in the first step in several metabolic pathways. HK3 is bound to the outer mitochondrial membrane. Its hydrophobic N-terminal sequence may be involved in membrane bindng. It is the predominant hexokinase isozyme expressed in insuline-responsive tissues such as skeletal muscle. The N- and Cterminal halves of this hexokinase show extensive sequence similarity to each other. The catalytic activity is associated with the C-terminus while regulatory function is

> associated wiht the N-terminus. Although found in NIDDM patients, genetic variations of

HK2 do not contribute to the disease.

Lehto, M., et al., Diabetologia 38(12):1466-1474 (1995). Vidal-Puig, A., et al., Diabetes reference:

44(3):340-346 (1995). Laakso, M., et al., Diabetes 44(3):330-334 (1995). Echwald, S.M., et

al., Diabetes 44(3):347-353 (1995). Shinohara, Y., et al., Cancer Let